Hosted on MSN1mon
FDA approves new pain medication as an alternative to opioids: What to know about JournavxThe medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of ...
Because of the recent approval by the FDA, it is anticipated payers will see an up-tick in the number of requests for this new drug. Because Journavx is not listed on the formulary, all requests ...
On Jan. 30, the FDA granted approval for Vertex's pain medication, Journavx. It's a non-opioid treatment for moderate to severe acute pain. For the healthcare industry, this can be a valuable ...
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...
RICHMOND, Va. (WRIC) — The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to severe acute pain in more than 20 years.
What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results